Compelling evidence challenges the simple classification of VISTA as an immunotherapy target, showing that in certain cancers, VISTA assumes stimulatory checkpoint-like functions and actively participates in the activation of anti-cancer immune responses. This evidence concerns the gene VSIR and cancer.